http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
강창준 ( Chang Joon Kang ),고경현 ( Kyung Hyun Koh ),김동훈 ( Dong Hoon Kim ),박상준 ( Sang Joon Park ),정재연 ( Jae Yeon Cheong ),김진홍 ( Jin Hong Kim ),조성원 ( Sung Won Cho ),이광재 ( Kwang Jae Lee ) 대한소화기기능성질환·운동학회 2008 Journal of Neurogastroenterology and Motility (JNM Vol.14 No.1
Pseudoachalasia or secondary achalasia is a rare motor abnormality mimicking primary achalasia. It has clinical, radiographic, and manometric features often indistinguishable from primary achalasia. The majority of reported cases of pseudoachlasia is associated with a neoplasm at or near the esophagogastric junction. A 62-year-old woman with inoperable pancreatic cancer presented with complaints of dysphagia, nausea and vomiting. Her endoscopic and esophageal manometric findings were compatible with achalasia. Abdominal CT scan revealed that gastroesophageal junction was compressed by a metastatic lymph node. We present a rare case of pseudoachalasia in which the primary cause of the disease was a pancreatic carcinoma.
항인지질 증후군과 연관된 급성 췌장염 및 비장 괴사 1예
고경현 ( Kyung Hyun Koh ),강창준 ( Chang Joon Kang ),김동훈 ( Dong Hoon Kim ),최용원 ( Yong Won Choi ),황재철 ( Jae Chul Hwang ),유병무 ( Byung Moo Yoo ),김진홍 ( Jin Hong Kim ) 대한소화기학회 2009 대한소화기학회지 Vol.53 No.1
There are various causes of splenic infarction. Antiphospholipid antibody is associated with numerous thromboembolic phenomena. We report a case of young male who presented with acute abdominal pain and was diagnosed as a case of splenic infarction and acute pancreatitis with antiphospholid syndrome. He was positive for anti-cardiolipin antibody, showed splenic infarction on abdominal CT scan. The patient`s clinical, laboratory and imaging finding were consistent with splenic infarction and acute pancreatitis associated with antiphospholipid syndrome. (Korean J Gastroenterol 2009;53:57-59)
증례 : 라미부딘 치료 후 클레부딘으로 전환한 만성 B형간염 환자에서 발생된 클레부딘 내성 1예: 연관 염기서열 분석
고경현 ( Kyung Hyun Koh ),강창준 ( Chang Joon Kang ),김동훈 ( Dong Hoon Kim ),최용원 ( Yong Won Choi ),김무정 ( Moo Jung Kim ),정재연 ( Jae Youn Cheong ),조성원 ( Sung Won Cho ) 대한소화기학회 2008 대한소화기학회지 Vol.52 No.5
Clevudine is a nucleoside analog of the unnatural β-L configuration which has potent antiviral activity against hepatitis B virus (HBV). Clevudine is expected to have similar pattern of resistance profile as lamivudine. However, there was no report on the mutation associated with clevudine resistance in patients with chronic hepatitis B. We report a case of young male patient with chronic hepatitis B who presented with clevudine resistance. The patient had received lamivudine therapy for 5 months with reduced serum HBV DNA levels. Then, lamivudine was switched to clevudine monotherapy. After the 6 months of clevudine therapy, the patient developed virologic breakthrough (>1.0×10(8) copies/mL) as well as biochemical breakthrough, which was associated with the presence of rtM204I plus rtL80I mutant. After switching from clevudine to adefovir, the viral load decreased with biochemical improvement. (Korean J Gastroenterol 2008;52:325-328)
연구논문 : 초치료 만성 B형간염 환자에서 엔테카비어 치료반응 및 관련 인자
이명희 ( Myoung Hee Lee ),임선교 ( Sun Gyo Lim ),전수진 ( Su Jin Jeon ),강창준 ( Chang Joon Kang ),조영주 ( Young Ju Cho ),김순선 ( Soon Sun Kim ),이다미 ( Da Mi Lee ),정재연 ( Jae Youn Cheong ),조성원 ( Sung Won Cho ) 대한간학회 2009 Clinical and Molecular Hepatology(대한간학회지) Vol.15 No.4
목적: 엔테카비어는 만성 B형간염의 초치료 환자에서 강력한 항바이러스 효과 및 낮은 내성률이 보고되고 있다. 본 연구에서는 단일 기관에서 경험한 엔테카비어의 혈청, 생화학, 바이러스반응을 관찰하고 엔테카비어의 치료반응과 연관된 인자를 규명하고자 하였다. 대상과 방법: 12개월 이상 1일 1회 0.5 mg의 엔테카비어를 경구 투여받은 114명의 만성 B형간염 환자를 대상으로 하였다. 초기바이러스반응은 치료 3개월 후 혈청 HBV DNA가 2,000 copies/mL 미만으로 감소한 경우로 정의하였다. 결과: 엔테카비어 투여 후 혈청 ALT값의 정상화는 치료 6개월, 12개월, 24개월에 각각 76명(68.5%), 85명(74.6%), 62명(81.6%)에서, HBV DNA PCR 음전은 각각 50명(43.9%), 81명(71.1%), 65명(85.5%)에서 관찰되었다. HBeAg 혈청소실은 6개월에 17명(36.2%), 12개월에 27명(43.5%), 24개월에 22명(56.4%), 혈청전환은 각각 8명(12.9%), 9명(14.5%), 6명(15.4%)에서 관찰되었다. HBV DNA PCR 음전을 예측할 수 인자는 단변량 분석에서 HBeAg 유무, 치료 전 혈청 AST치, 혈청 HBV DNA치, 초기바이러스반응 유무였고, 다변량 분석에서 초기바이러스반응이 독립적인 인자였다[P<0.001, OR=7.286(2.663~19.932)]. HBeAg의 혈청소실은 혈청 알부민치와 혈소판 수치가 낮은 경우, 혈청 AST치가 높은 경우, 간경변을 동반한 경우와 초기바이러스반응이 있는 경우에 빈번하게 발생하였고, 혈청 알부민[P=0.041, OR=0.232(0.057~0.945)]치와 초기바이러스반응[P=0.005, OR=7.017(1.799~27.378)]이 독립적인 예측인자였다. 결론: 엔테카비어는 만성 B형간염의 초치료 환자에서 우수한 치료반응을 보였으며, 치료 3개월째 초기바이러스반응은 HBV DNA 음전 및 HBeAg 소실의 독립적 예측인자였다. Background/Aims: Entecavir is a potent and selective guanosine analogue that has demonstrated a significant antiviral efficacy against hepatitis B virus (HBV). The aim of this study was to characterize the response to entecavir and to examine the factors affecting that response. Methods: We administered 0.5 mg of entecavir once daily for more than 12 months to 114 naive chronic hepatitis B (CHB) patients. We measured the levels of liver enzymes, serological markers, and serum HBV DNA at 3-month interval. Results: Normalization of serum alanine aminotransferase levels was observed in 68.5% (76/114), 74.6% (85/114), and 81.6% (62/76) of patients after 6, 12, and 24 months of therapy, respectively. HBV DNA levels of <50 copies/mL (as evaluated by polymerase chain reaction) were observed in 43.9% (50/114), 71.1% (81/114), and 85.5% (65/76) of patients after 6, 12, and 24 months, respectively. Viral breakthrough was not observed. The rates of HBeAg loss and seroconversion were 43.5% (27/62) and 14.5% (9/62), respectively, after 12 months of therapy, and 56.4% (22/39) and 15.4% (6/39) after 24 months. The independent factor associated with PCR negativity was early virologic response (EVR; HBV DNA <2,000 copies/mL after 3 months of therapy, P<0.001). The independent factors predicting HBeAg loss were found to be serum albumin levels (P=0.041) and EVR (P=0.005). Conclusions: Entecavir induced excellent biochemical and virologic responses in naive CHB patients. EVR was an independent factor for predicting HBV PCR negativity and HBeAg loss. (Korean J Hepatol 2009;15:446-453)
라미부딘 내성 만성 B형간염 환자에서 아데포비어 단독요법 후 라미부딘 추가투여의 효과
조영주 ( Young Ju Cho ),정재연 ( Jae Youn Cheong ),이명희 ( Myoung Hee Lee ),전수진 ( Su Jin Jeon ),이윤철 ( Yoon Chul Lee ),임선교 ( Sun Gyo Lim ),강창준 ( Chang Joon Kang ),조성원 ( Sung Won Cho ) 대한소화기학회 2010 대한소화기학회지 Vol.56 No.2
Background/Aims: Add on adefovir (ADV) to ongoing lamivudine (LAM) has been recommended as a standard therapy for the treatment of LAM resistance. In the past, switch to ADV monotherapy was suggested as an option for the treatment of LAM resistance, leading to frequent development of ADV resistance. However, ADV monotherapy has been still used in LAM-resistant patients because of low cost in Korea. The aims of this study were to evaluate the virologic response and virologic breakthrough during adding on LAM in LAM-resistant patients receiving ADV monotherapy. Methods: The study population comprised 99 patients with LAM-resistance. We divided them into 3 groups (Group 1: switch to ADV monotherapy, N=58, Group 2: add on ADV to ongoing LAM, N=25, Group 3: add on LAM to ADV monotherapy, N=16). HBV DNA levels were assessed at baseline and every 3 months during therapy. Serum HBV DNA levels were measured by bDNA assay or the COBAS TaqMan(TM) HBV test. Results: The median treatment duration for group 1, group 2, and group 3 was 42.0, 20.6, and 31.8 (18.7 mon. of ADV+13.1 mon. of LAM) months, respectively. Cumulative rate of virologic breakthrough in group 1 was 5.2%, 19.0%, and 25.9% at 12, 24, and 36 months of treatment, respectively. Virologic breakthrough was not detected in group 2 and group 3 (p=0.016, group 1 vs. group 2 or 3). In group 3, median serum HBV DNA levels were 4.22 log(10) copies/mL prior to LAM administration. Median serum HBV DNA changes from baseline (log10 copies/mL) were ?0.91, ?1.93, ?1.87 and ?1.74 at week 12, 24, 36 and 48, respectively. Conclusions: Later add on LAM to ADV monotherapy prevented the development of ADV resistance in patients with LAM resistance effectively, comparable to ADV add on to continuing LAM therapy. (Korean J Gastroenterol 2010;56:83-89)